EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Miglustat: Substrate Reduction Therapy for Lysosomal Storage Disorders Associated with Primary Central Nervous System Involvement

Gregory M Pastores

Recent Patents on CNS Drug Discovery · 2006

DOI: 10.2174/157488906775245282 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Recent Patents on CNS Drug Discovery, 2006. Verfasst von Gregory M Pastores. Beteiligte Einrichtung: Neurogenetics Unit, Department of Neurology and Pediatrics, New York University School of Medicine, New York, NY, USA. gregory.pastores@med.nyu.edu. Die Arbeit wurde bisher 13-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

1-DeoxynojirimycinAnimalsBrainBrain DiseasesEnzyme InhibitorsHumansLysosomal Storage Diseases

Substanzen

Enzyme Inhibitors1-Deoxynojirimycinmiglustat

Autor:innen und Institutionen

  • Neurogenetics Unit, Department of Neurology and Pediatrics, New York University School of Medicine, New York, NY, USA. gregory.pastores@med.nyu.edu

Zitieren

APA

Pastores, G. M. (2006). Miglustat: Substrate Reduction Therapy for Lysosomal Storage Disorders Associated with Primary Central Nervous System Involvement. Recent Patents on CNS Drug Discovery. https://doi.org/10.2174/157488906775245282

Vancouver

Pastores GM. Miglustat: Substrate Reduction Therapy for Lysosomal Storage Disorders Associated with Primary Central Nervous System Involvement. Recent Patents on CNS Drug Discovery. 2006. doi:10.2174/157488906775245282

BibTeX
@article{Pastores2006,
  author = {Pastores, Gregory M},
  title = {Miglustat: Substrate Reduction Therapy for Lysosomal Storage Disorders Associated with Primary Central Nervous System Involvement},
  journal = {Recent Patents on CNS Drug Discovery},
  year = {2006},
  doi = {10.2174/157488906775245282}
}
Kostenlos starten →